跳至主要内容
临床试验/NCT06958237
NCT06958237已完成不适用

Evaluation of Performance and Safety of the Medical Device: Salicylic Acid Wart Patch for the Treatment of Common Warts and Plantar Warts

Langsteiner sp. z o.o.2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年5月19日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
2
主要终点
reduction in the size of the lesion

研究概览

简要总结

Common and plantar warts are a type of skin lesion caused by infection with the human papilloma virus. The incidence of warts is relatively high, with an estimated few to several per cent of the adult population affected. An even higher incidence of dermal warts is reported in the child and adolescent population, where it reaches nearly twenty per cent. The human papilloma virus (HPV) multiplies in the epidermal cells, leading to the formation of a skin lesion with a hyperkeratotic, uneven surface, called a wart. HPV infection can lead to various types of warts: including common warts, plantar warts, flat warts or condyloma acuminatum. Warts belong to skin lesions of a benign and self-limiting nature. Because of this, treatment of warts is often not applied. However, it is necessary to emphasise that warts, including in particular plantar warts, can be a source of pain as well as lead to psychological discomfort for the patient. Additionally, untreated warts are a potential source of subsequent infections.

For this reason, a variety of methods are used to treat warts, with the primary aim of removing the layer of diseased epidermis, as well as limiting the spread of the virus. The methods used to treat warts can be divided according to the nature of the agent used in the treatment - physical or chemical. Physical methods include cryotherapy, photodynamic therapy and surgical or laser wart removal. Chemical methods for the treatment of warts will be the use of ointments and solutions of substances such as salicylic acid, 5-fluorouracil, glycolic acid or purine acid. In addition, the treatment of warts also includes methods based on an occlusive action, involving the use of a barrier that shields the skin lesion and stops the spread of the virus.

This protocol concerns a study of salicylic acid wart patches. The aim of the study is to determine the efficacy and safety of their use in the treatment of common and plantar warts. The patches allow covering the lesion and the salicylic acid contained in them at a concentration of 40% has a keratolytic action allowing exfoliation of excessive epidermal proliferation caused by HPV infection. In addition, the mass of the product includes lanolin, which has an epidermal softening effect. The patches are intended for a patient population over six years of age, with common and plantar warts. The primary endpoints analysed in the study will be reduction in lesion size (assessed by dermatoscopic measurement), change in the number of warts in the area of the main wart-like lesion, occurrence of further dermal wart-like lesions in the treated area and incidence of adverse reactions. In addition, secondary endpoints to be analysed are reduction in lesion size (users' visual assessment), reduction in lesion visibility (users' visual assessment) and usability of the device.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • giving consent to participate in the clinical trial (consent of the minor's guardian where applicable);
  • presence of at least 1 wart (common/plantar) on the body, with a lesion up to 1 cm in diameter;
  • age, at least 6 years.

排除标准

  • failure to meet at least 1 inclusion criterion;
  • the patient has a known hypersensitivity to salicylic acid, salicylates or any other component of the patch;
  • patients with renal impairment (renal failure);
  • patients with skin conditions (e.g. inflammation, wounds, eczema) at the site of application,
  • patients concurrently using other topical treatments in the area of the wart,
  • diabetic patients.

结局指标

主要结局

reduction in the size of the lesion

时间窗: 30 minutes (single visit)

reduction in the size of the lesion assessed by measuring with a dermatoscope

change in the number of warts in the area of the main wart-like lesion

时间窗: 30 minutes (single visit)

change in the number of warts in the area of the main wart-like lesion as assessed by the dermatologist

occurrence of further dermal wart-like lesions in the treated area

时间窗: 30 minutes (single visit)

occurrence of further dermal wart-like lesions in the treated area as assessed by the dermatologist

Adverse events

时间窗: 30 minutes (single visit)

Adverse events occuring during treatment of warts

次要结局

  • reduction in lesion size(30 minutes (single visit))
  • reduction in the visibility of the lesion(30 minutes (single visit))
  • usability of the device(30 minutes (single visit))

研究者

发起方
Langsteiner sp. z o.o.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验